** Drugmaker Halozyme HALO.O sues Merck MRK.N over a subcutaneous version of cancer drug Keytruda, which HALO says uses a drug delivery technology patented by it
** Shares of HALO rise 1% to $59.03
** Last month, MRK, who is banking on the new version of Keytruda to protect it against a patent expiry in 2028, said that it plans to launch the drug on October 1
** The ultimate outcome of Halozyme's lawsuit should have no impact on the company's current or future licenses, revenues, or programs related to a newer drug delivery technology — TD Cowen
** "We see significant upside opportunity for Halozyme if they are awarded a royalty on Keytruda SC sales" — brokerage
** Including session's move, HALO stock up 23.6% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.